Successfully treated congenital cystic adenomatoid malformation by open fetal surgery
A care-compliant case report of a 5-year follow-up and review of the literature

Dazhi Fan, MD<sup>a,b,c</sup>, Shuzhen Wu, MD<sup>a,b</sup>, Rui Wang, BD<sup>a,b</sup>, Yi Huang, PhD<sup>a,b</sup>, Yao Fu, MD<sup>a,b</sup>, Wen Ai, MD<sup>a,b</sup>, Meng Zeng, BD<sup>a,b</sup>, Xiaoling Guo, BD<sup>a,b</sup>,* Zhengping Liu, MD<sup>a,b</sup>,*

**Abstract**

**Background:** Congenital cystic adenomatoid malformation (CCAM) is a rare hamartomatous cystic lesion. Open fetal surgery currently provides a potential therapeutic option for management of a fetus with CCAM diagnosis.

**Case Summary:** A 22-year-old G2P0 woman presented at 21 7/12 weeks’ gestation for evaluation of a fetus with a left lung lesion and diagnosed as CCAM at 28 1/12 weeks’ gestation. Open fetal surgery was performed to resect the lesion at 29 1/12 weeks’ gestation under deep maternal general anesthesia. The mother presented at 3 1/12 weeks after open fetal surgery with preterm premature rupture of membranes (PPROM) and underwent cesarean delivery at 32 1/12 weeks’ gestation. A vigorous woman infant of 1955g, with good Apgar score, was delivered. At 1 month, 4 years, and present, 5 years after birth, she has continued to do well without any obvious deficit and both respiration and circulation were well maintained.

**Conclusion:** We present one case of CCAM which was cured by open fetal surgery and continued to do well at follow-up of 5 years. The success of treatment provided preliminary experience for further carrying out such interventions in China.

**Abbreviations:**
- CCAM = congenital cystic adenomatoid malformation
- CPAM = congenital pulmonary adenomatoid malformation
- CT = computed tomography
- CVR = cystic volume ratio
- EXIT = Ex-utero intrapartum therapy
- MRI = magnetic resonance imaging
- PPROM = preterm premature rupture of membranes

**Keywords:** case report, congenital cystic adenomatoid malformation, follow-up, open fetal surgery

1. Introduction

Congenital cystic adenomatoid malformation (CCAM), also called congenital pulmonary adenomatoid malformation (CPAM), is a rare hamartomatous cystic lesion, firstly described by Ch’In and Tang in 1949<sup>[1]</sup> and classified into 3 subtypes in 1977<sup>[2]</sup>, and expanded into 5 types with a new name as CPAM by Stocker in 2002<sup>[3]</sup>. In Canada, the condition occurs in 1 in 25,000 to 35,000 births<sup>[4]</sup>. Our previous study noted that the occurrence is approximately 3.34:10,000 in China<sup>[5]</sup>, nearly 10 times higher than the level reported in Canada. Prenatal intervention of CCAMs was determined by the size and classification of the lesion as well as the presence of fetal hydrops. Open fetal surgery currently provides a potential therapeutic option for management of the fetus with CCAM diagnosis and massive nonimmune hydrops. We present one case of CCAM, which was cured by open fetal surgery and continued to do well after a follow-up of 5 years. To our knowledge, this is the first report in China.

2. Case presentation

This case presentation has been consented by the family and approved by the ethics committee of South Medical University Affiliated Maternal & Child Health Hospital of Foshan.

A 22-year-old G2P0 woman presented at 21 7/12 weeks’ gestation for evaluation of a fetus with a left lung lesion. A detailed ultrasound examination considered pulmonary sequestration, but pulmonary cystadenoma could not be totally excluded. Serial ultrasonographic monitoring demonstrated an increasing size of the lesion of the left lung and the heart was shifted to the right. The ultrasound examination revealed a 5.6cm × 5.0cm × 5.0cm mass at 28 1/12 weeks’ gestation (Fig. 1). The presentation was believed to be consistent with a CCAM. The cystic adenomatoid malformation volume ratio (CVR) was 2.8. Amniocentesis confirmed normal karyotype and no other anatomic abnormalities were present on detailed ultrasonographic survey.
Nonimmune hydrops were not found before operation, and the heart function was well preoperatively (Fig. 2). Given the continued growth of the lung mass, the concern for the progression of hydrops and fetal demise, and the significant pulmonary hypoplasia believed incompatible with survival secondary to mass effect, multidisciplinary counseling was performed regarding open fetal surgery. After full evaluation and counseling by the fetal surgery team, the patient and her family wished to proceed with intrauterine surgery. Informed consent was obtained in accordance with the surgery protocol, and the open fetal surgery was approved by the ethics committee of South Medical University Affiliated Maternal & Child Health Hospital of Foshan.

A maternal hysterotomy, left fetal thoracotomy and CCAM resection were performed at 29\(\frac{2}{7}\) weeks' gestation (May 15, 2011) under deep maternal general anesthesia. Indomethacin and antibiotics were given preoperatively, and ritodrine hydrochloride provided the necessary uterine relaxation. Sterile intraoperative sonography delineated both the fetal and placental position. The uterine incision (about 10 cm) was made at the edge of the placenta. The left fetal hand was delivered, intravenous access obtained, and a fetal pulse oximeter was placed. A left fetal thoracoabdominal incision was made based in the fifth intercostal space. Continuous fetal echocardiography assessed ongoing cardiac function and directed resuscitation requirements. After the thoracotomy, the mass was slowly delivered from the chest cavity and the CCAM resection was initiated. The fetal chest wall was closed and the fetus returned to the uterine cavity. An intrauterine dose of dexamethasone (10 mg) and ampicillin (4 g) were administered after the amniotic cavity was filled with warmed (37°C) lactated Ringer solution. And the uterine and abdominal incisions were closed in layers. The mother tolerated the procedure well and was given atosiban and ritodrine hydrochloride after the surgery. Continuous fetal echocardiography confirmed recovery of fetal heart function after the intraoperative fetal resuscitation.

Postoperatively, the mother was treated with intravenous magnesium sulfate, indocin, and transitioned to nifedipine for the remainder of the pregnancy to maintain uterine quiescence. The pathology from the fetal excision demonstrated pulmonary mass hyperplasia consistent with CCAM-like changes (Fig. 3). The mother presented at 32\(\frac{6}{7}\) weeks after open fetal surgery with preterm premature rupture of membranes (PPROM) and underwent cesarean delivery at 32\(\frac{6}{7}\) weeks' gestation. A vigorous woman infant of 1955 g (50th centile), with good Apgar score, was delivered. The baby's thoracoabdominal incision was well healed at birth without any evidence of fluid leakage. At 1 month, 4 years, and present, 5 years after birth, she has continued to do well without any obvious deficit and both respiration and circulation were well maintained (Fig. 4A, B).

Progression of the patient’s condition and accompanying interventions are illustrated in a flowchart (Fig. 5). The surgery and follow-up are displayed in supplemental video, http://links.lww.com/MD/B514.

### 3. Discussion

CCAM is a rare fetal pulmonary lesion, it can be diagnosed in antenatal period by ultrasonography. It is the most frequently observed lung lesion (25%) among all subtypes of congenital lesions.
pulmonary malformations, and most cases are found in neonates and infants while pulmonary malformations are infrequent in adulthood.\textsuperscript{[8]} Lung lesions are diagnosed nowadays mainly by prenatal ultrasound imaging, but magnetic resonance imaging can be very useful in the differential diagnosis of bronchogenic cysts, bronchial atresia, or multilobe involvement. Almost 100\% of lung cysts could be detected at the routine 18 to 20-week scan.\textsuperscript{[9]} It is extremely variable in the clinical spectrum and natural history of CCAMs, especially with respect to lesion growth during the canalicular period (17–29 weeks). It has been reported that without nonimmune hydrops fetalis, lung masses can be spontaneously disappear in the third pregnancy.\textsuperscript{[10]} However, the development of nonimmune hydrops fetalis portends 100\% mortality rate in the presence of CCAM.\textsuperscript{[11]} Although spontaneous resolution of nonimmune hydrops have been reported, resolution of hydrops in association with fetal lung lesions is exceedingly rare.\textsuperscript{[12]}

Without prenatal intervention, the presence of bilateral disease and hydrops fetalis are indicators of poor outcome,\textsuperscript{[13]} whereas early detection, polyhydramnios and mediastinal shift are not poor prognostic signs in the fetus with a CCAM.\textsuperscript{[14,15]} It will present significant cardiorespiratory compromise at birth in some postnatal patients. However, it can also be asymptomatic. When the other symptoms, such as recurrent respiratory infections, appear, it may be incidentally diagnosed in postnatal life when a chest computed tomography (CT) or X-ray is performed.

With advances in antenatal ultrasonography, CCAM has been increasingly diagnosed. Various ultrasonography features, including the size and type, presence of mediastinal shift and hydropic change, have been associated with a poor prognosis. Up till now, the exact mechanisms of the congenital disease remain unknown, although research found the lesion coexists with recombinant chromosome 18,\textsuperscript{[16]} and this pathology of karyotype could not be ruled out by certain.

Although postnatal intervention is possible, with increasing in utero diagnosis with ultrasound, the condition has been treated during pregnancy (prenatal intervention) with the aim of decreased disability and morbidity for the neonate and infant. Normal karyotype and without other detected anomalies are the major selection criteria for prenatal intervention. There have been several interventions for the treatment of the CCAM. The interventions mainly include amniocentesis treatment,\textsuperscript{[17]} steroid therapy,\textsuperscript{[12,18–20]} thoracoamniotic shunts,\textsuperscript{[21]} laser ablation,\textsuperscript{[22]} and surgical treatments.\textsuperscript{[23,24]}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{Chest radiographs. (A) At 25 days after birth. (B) At 4 years after birth.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5.png}
\caption{Progression of the patient’s condition and accompanying interventions.}
\end{figure}
In conclusion, we present 1 case of CCAM that was cured and continued to do well follow-up 5 years by open fetal surgery in China. The success of treatment provided preliminary experience for further carrying out such interventions.

Acknowledgments

The author(s) thank the patient and her family for participation in the study. Thanks to Zhanhui Lu, in their department, helps them to show the ultrasound image of the hydrops and heart before operation.

References

[1] Ch'In KY, Tang MY. Congenital adenomatoid malformation of one lobe of a lung with general anasarca. Arch Pathol 1949;48:221–9.
[2] Stocker JT, Madewell JE, Drake RM. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Hum Pathol 1977;8:153–71.
[3] Stocker JT. Congenital pulmonary airway malformation: a new name and an expanded classification of congenital cystic adenomatoid malformation of the lung. Histopathology 2002;41:424–31.
[4] Laberge JM, Flageole H, Pugash D, et al. Outcome of the prenatally diagnosed congenital cystic adenomatoid lung malformation: a Canadian experience. Fetal Diagn Ther 2001;16:178–86.
[5] Guo XL, Wang Q, Liu ZP, et al. Clinical analysis on prevalence and pregnancy outcome of fetal congenital cystic adenomatoid malformation in Foshan from 2007 to 2012. Mater Child Health Care China 2012;2014:4927–31.
[6] Liu J, Ye Y, Dong Z, et al. Anesthesia management for open fetal intrauterine surgery. Clin Exp Obstet Gynecol 2013;40:403–6.
[7] Liu ZP, Guo XL, Liu Y, et al. Classification of complete placenta previa (CPP) and clinic significance. Mater Child Health Care China 2008;23:1964–7.
[8] Zhang ZJ, Huang MX. Children with congenital cystic adenomatoid malformation of the lung CT diagnosis. Int J Clin Exp Med 2015;8:4415–9.
[9] Lakhoo K. Management of congenital cystic adenomatous malformations of the lung. Arch Dis Childhood Fetal Neonatal Ed 2009;94:F73–6.
[10] van Leeuwen K, Teitelbaum DH, Hirschl RB, et al. Prenatal diagnosis of congenital cystic adenomatoid malformation and its postnatal presentation, surgical indications, and natural history. J Pediatr Surg 1999;34:794–8. discussion 798–99.
[11] Adzick NS. Management of fetal lung lesions. Clin Perinatol 2003;30:481–92.
[12] Tsao K, Hawgood S, Vu L, et al. Resolution of hydrops fetalis in congenital cystic adenomatoid malformation after prenatal steroid therapy. J Pediatr Surg 2003;38:508–10.
[13] Mann S, Wilson RD, Bebbington MW, et al. Antenatal diagnosis and management of congenital cystic adenomatoid malformation. Semin Fetal Neonatal Med 2007;12:477–81.
[14] Davenport M, Warne SA, Cacciaguerra S, et al. Current outcome of antenatally diagnosed cystic lung disease. J Pediatr Surg 2004;39:549–56.
[15] Usui N, Kamata S, Sawai T, et al. Outcome predictors for infants with cystic lung disease. J Pediatr Surg 2008;43:603–6.
[16] Roberts D, Sweeney E, Walkinshaw S. Congenital cystic adenomatoid malformation of the lung coexisting with recombinant chromosome 18. A case report. Fetal Diagn Ther 2001;16:65–7.
[17] Brown MF, Lewis D, Brouillette RM, et al. Successful prenatal management of hydrops, caused by congenital cystic adenomatoid malformation, using serial aspirations. J Pediatr Surg 1995;30:1098–9.
[18] Morris LM, Lim FY, Livingston JC, et al. High-risk fetal congenital pulmonary airway malformations have a variable response to steroids. J Pediatr Surg 2009;44:60–5.
[19] Curran PF, Jelin EB, Rand L, et al. Prenatal steroids for microcystic congenital cystic adenomatoid malformations. J Pediatr Surg 2010;45:145–50.
[20] Peranteau WH, Wilson RD, Liechty KW, et al. Effect of maternal betamethasone administration on prenatal congenital cystic adenomatoid malformation growth and fetal survival. Fetal Diagn Ther 2007;22:365–71.
[21] Wilson RD, Baxter JK, Johnson MP, et al. Thoracoamniotic shunts: fetal treatment of pleural effusions and congenital cystic adenomatoid malformations. Fetal Diagn Ther 2004;19:413–20.
[22] Bruner JP, Jarnagin BK, Reinisch L. Percutaneous laser ablation of fetal congenital cystic adenomatoid malformation: too little, too late? Fetal Diagn Ther 2000;15:359–63.

[23] Adzick NS. Open fetal surgery for life-threatening fetal anomalies. Semin Fetal Neonatal Med 2010;15:1–8.

[24] Liu ZP, Liu GQ, Liu JP, et al. The ex utero intrapartum therapy procedure for fetal congenital lesions. Mater Child Health Care China 2011;26:3107–8.

[25] Merchant AM, Peranteau W, Wilson RD, et al. Postnatal chest wall deformities after fetal thoracocystentamniotic shunting for congenital cystic adenomatoid malformation. Fetal Diagn Ther 2007;22:435–9.

[26] Min JY, Won HS, Lee MY, et al. Intrauterine therapy for macroadenycystic congenital cystic adenomatoid malformation of the lung. Obstet Gynecol Sci 2014;57:102–8.

[27] Harrison MR, Adzick NS, Jennings RW, et al. Antenatal intervention for congenital cystic adenomatoid malformation. Lancet 1990;336:965–7.

[28] Adzick NS, Harrison MR, Flake AW, et al. Fetal surgery for cystic adenomatoid malformation of the lung. J Pediatr Surg 1993;28:806–12.

[29] Kahn L, Mbabuike N, Valle-Giler EP, et al. Fetal surgery: the Ochsner experience with in utero spina bifida repair. Ochsner J 2014;14:112–8.

[30] Liu ZP, Liu GQ, Liu JP, et al. Open fetal surgery for congenital cystic adenomatoid malformation: A case report. Chin J Obstet Gynecol 2012;47:297–8.

[31] Hedrick HL, Flake AW, Crombleholme TM, et al. The ex utero intrapartum therapy procedure for high-risk fetal lung lesions. J Pediatr Surg 2005;40:1038–43, discussion 1044.

[32] Cass DL, Olutoye OO, Cassady CI, et al. EXIT-to-resection for fetuses with large lung masses and persistent mediastinal compression near birth. J Pediatr Surg 2013;48:138–44.

[33] Lazar DA, Cass DL, Dishop MK, et al. Fetal lung interstitial tumor: a cause of late gestation fetal hydrops. J Pediatr Surg 2011;46:1263–6.

[34] Stanton M, Davenport M. Management of congenital lung lesions. Early Hum Dev 2006;82:289–95.

[35] Tsai AY, Liechty KW, Hedrick HL, et al. Outcomes after postnatal resection of prenatally diagnosed asymptomatic cystic lung lesions. J Pediatr Surg 2008;43:513–7.

[36] Jaffe A, Chitty LS. Congenital cystic adenomatoid malformations may not require surgical intervention. Arch Dis Child Fetal Neonatal Ed 2006;91:F464.

[37] Chetcuti PA, Crabbe DC. CAM lungs: the conservative approach. Arch Dis Child Fetal Neonatal Ed 2006;91:F463–4.

[38] Harrison MR, Adzick NS. Fetal surgical techniques. Semin Pediatr Surg 1993;2:136–42.

[39] Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. Am J Obstet Gynecol 1998;179:884–9.